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Abstract Angiogenesis relies on endothelial cells prop-
erly processing signals from growth factors provided in
both an autocrine and a paracrine manner. These mitogens
bind to their cognate receptor tyrosine kinases (RTKs) on
the cell surface, thereby activating a myriad of complex
intracellular signaling pathways whose outputs include cell
growth, migration, and morphogenesis. Understanding how
these cascades are precisely controlled will provide insight
into physiological and pathological angiogenesis. The
Sprouty (Spry) family of proteins is a highly conserved
group of negative feedback loop modulators of growth
factor-mediated mitogen-activated protein kinase (MAPK)
activation originally described in Drosophila. There are
four mammalian orthologs (Spry1-4) whose modulation of
RTK-induced signaling pathways is growth factor – and
cell context – dependant. Endothelial cells are a group of
highly differentiated cell types necessary for defining the
mammalian vasculature. These cells respond to a plethora
of growth factors and express all four Spry isoforms, thus
highlighting the complexity that is required to form and
maintain vessels in mammals. This review describes Spry
functions in the context of endothelial biology and angio-
genesis, and provides an update on Spry-interacting
proteins and Spry mechanisms of action.
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FGF Fibroblast growth factor
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MAPK Mitogen-activated protein kinase
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phosphatase 2
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Spred Spry-related proteins with Enabled/vasodilator-
stimulated phosphoprotein homology 1 domain
SPR Spry-related domain
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Introduction
Receptor tyrosine kinases (RTKs) have been at the forefront
of cancer research for many years due to their pivotal role in
cancer biology as prognostic indicators and therapeutic tar-
gets [1, 2]. Thus, the elucidation of RTK signaling cascades
and their regulatory networks has been an important objec-
tive of many laboratories, especially since angiogenesis and
the angiogenic switch necessitate activation of various
growth factor receptors [3–5]. The formation of the vascu-
lature by the endothelium and supporting stroma via
branching morphogenesis is analogous to what is observed in
the development of tubular networks found in other tissues
(e.g. lung, kidney, mammary gland, and placenta) [6, 7].
Growth factors, such as the vascular endothelial growth
factors (VEGFs), fibroblast growth factors (FGFs), epider-
mal growth factor (EGF), ephrins, and angiopoietins (Angs),
in conjunction with their cognate receptors play a crucial role
in blood vessel formation in normal and pathological settings
(reviewed in [8, 9]). The majority of RTKs, serving as
gatekeepers for these extracellular growth factors, among
several signaling pathways, activate the extracellular signal-
regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) signaling cascade composed of Raf1, MAPK and
ERK kinase (MEK), and MAPK (Fig. 1a). These pathways
are precisely controlled spatio-temporally by the activity of
various modulatory proteins in a cell context-dependant
manner [10–12].
In vertebrates, such modulators of RTK signaling include
the members of the Sprouty (Spry) family of proteins, com-
prising various Spry and Spred (Spry-related proteins with
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Fig. 1 Spry mechanisms of action in growth factor signaling
pathways. (a) Canonical signal transduction in the absence of Spry.
Upon ligand binding, RTKs can activate MAPK in a Ras-dependent
manner via the adapter protein Grb2 and Sos1-mediated activation of
Ras, Raf1, MEK, and eventually MAPK. Another conserved RTK
pathway that can be activated is that mediated by PLCc, which
converts phosphatidylinositol [4, 5]-bisphosphate (PIP2) into two
second messengers: inositol [1, 4, 5] trisphosphate (IP3) and
diacylglycerol (DAG), leading to calcium (Ca2+) mobilization. Both
DAG and Ca2+ activate PKC, which in turn phosphorylates Raf1, thus
leading to MAPK activation. (b) Spry-mediated inhibition of the FGF
signaling pathway. Spry is serine phosphorylated on multiple residues
in unstimulated cells and at least serines 112 and 115 are dephos-
phorylated by PP2A upon FGF stimulation [23, 57]. Also, Spry
phosphorylation at Y55 by a Src-like kinase and by an unknown
kinase (X) at Y227 is required for Spry to inhibit FGF-induced
activation of MAPK [24, 48, 52, 56]. Under some conditions, Spry
binding to Grb2 is sufficient to inhibit FGF-induced activation of
MAPK, while in others Grb2 association is not required [42, 55].
Also, Spry binding to Sos1 and potentially to Raf1 inhibits FGF-
stimulated MAPK activity [18, 43]. (c) Spry-mediated potentiation of
the EGF signaling pathway. Upon EGF binding, Spry is tyrosine
phosphorylated and competes with EGFR for binding to c-Cbl. By
interacting with c-Cbl, Spry becomes ubiquitinylated and eventually
degraded, allowing for sustained EGFR signaling [44–46, 61, 80]. (d)
Spry-mediated inhibition of the VEGF signaling pathway. The
VEGFR signals via the PLCc/PKC pathway [66]. Upon VEGF
activation, Spry interacts with Raf1 via its RBD and inhibits
activation of MAPK. Tyrosine phosphorylation of Spry is not
required for this activity [67]. pY and pS denote phosphorylated
tyrosine and serine residues, respectively. In this schematic, using
Spry2 as the representative Spry isoform, pY55 and pY227 represent
the N- and C- terminal phospho-tyrosines
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Enabled/vasodilator-stimulated phosphoprotein homology
1 domain) isoforms. Depending on the cell type and physi-
ological conditions, Sprys and Spreds modulate RTK
signaling (and sometimes also signaling by G-protein-cou-
pled receptors) by mainly repressing the MAPK pathway
(see below). The founding member of the family, Drosophila
Spry (dSpry), was initially described as a negative feedback
loop inhibitor of FGF-mediated branching of the Drosophila
trachea [13]. There are four mammalian dSpry homologs,
Spry1-4 (reviewed in [14–18]) and four Spred proteins,
Spred1-3 and EVE-3 (a splice variant of Spred-3) (reviewed
in [19]) that all contain the highly conserved cysteine-rich
Sprouty-related (SPR) domain. The expression of Spry1, 2,
and 4 is widespread in embryos and adults, while that of
Spry3 is believed to be more restricted (brain and testes in
adult tissues) [20, 21]. Like dSpry, the expression of mam-
malian Spry proteins is induced by the growth factor
cascades that they target [22–24]. Upon growth factor acti-
vation, a subset of Spry proteins translocate to the cell
membrane where MAPK inhibition presumably occurs [23,
25, 26]. Spry proteins can modulate MAPK activation
induced by several stimuli, including EGF, FGF, VEGF,
platelet-derived growth factor (PDGF), nerve growth factor,
hepatocyte growth factor, insulin, stem cell factor/kit ligand,
glial-derived growth factor (GDNF), brain-derived neuro-
trophic factor, and T-cell receptor activation [17, 18, 22, 24,
27–30]. This review will discuss Spry protein function in the
context of endothelial cells and provide an update on their
mechanism of action, Spry-interacting partners, and regu-
lation of Spry stability and activity.
Spry expression
Endothelial cells can be cultured in vitro to form capillary-
like structures and various molecular approaches have been
employed to identify genes required for tube/capillary for-
mation. For example, using subtractive cDNA library
hybridization, proliferating human microvascular endothe-
lial cells (HMVECs) were compared to those that
differentiate and form tube-like structures on Matrigel [31].
These studies identified several transcripts, including Spry2
mRNA, which were differentially enriched in tube-forming
HMVECs versus proliferating HMVECs. Also, in an early
DNA microarray study, Spry1 was found highly upregulated
in human umbilical vein endothelial cells (HUVECs) during
capillary morphogenesis in a three-dimensional collagen
matrix [32]. The increase in Spry1 mRNA abundance coin-
cided with a decrease in FGF2 mRNA. Another mRNA
following a pattern similar to that of Spry1 was Ang2, an
antagonistic ligand of the Tie2 receptor, and one of the most
upregulated transcripts detected in this experiment [33].
Similarly, Spry1, along with Ang2 and other mRNAs, was
found enriched in microvascular endothelial cells, suggest-
ing a specific role for Spry1 in capillary tube formation [34].
More recently, a comprehensive expression analysis of
FGFs, FGF receptors (FGFRs), and various FGF signaling
inhibitors was performed in primary human endothelial and
vascular smooth muscle cells (SMCs) [35]. This study
demonstrated that HUVECs and SMCs express a variety of
FGFs (FGF1, 2, 5, 7, 8, 11, 12, 16, 18), FGFRs (FGFR1c, 2c,
3c) and FGF signaling antagonists including all four Spry
isoforms. Furthermore, in spheroid co-cultures consisting of
HUVECs and SMCs, the repertoire of these various com-
ponents of the FGF signaling cascade did not significantly
change, suggesting that both cell types behaved as an entity
rather than as two distinct cell populations. Thus, endothelial
cells express all four isoforms of Spry, underlining the need
for specialization, yet maintaining redundancy in these
highly differentiated cells.
More recently, additional insights into the regulation of
Spry expression in endothelial cells have been reported
[36]. The highly conserved FoxO genes, FoxO1, FoxO3a,
and FoxO4, are expressed in endothelial cells, and null
mice for FoxO1 and FoxO3 display vascular phenotypes
(reviewed in [37]). Moreover, mice deficient for all three
FoxO genes exhibited tissue-specific hemangiomas result-
ing in premature death [36]. Spry2 was identified by
microarray analysis as an important FoxO target gene in
affected endothelial cells. The Spry2 promoter contained
FoxO-binding elements, and Spry2 expression correlated
with FoxO deletion in a tissue-specific manner. Further-
more, in liver endothelial cells, Spry expression was lost
upon FoxO deletion, an effect not observed in lung endo-
thelial cells. Phenocopying Spry2 loss by RNA interference
technology confirmed that endothelial cells lacking Spry2
were more proliferative and less susceptible to apoptosis.
Apparently, both the Fox and the Ets transcription factor
families are required for proper angiogenesis, and for
endothelial cell function and differentiation [37]. Also, the
human Spry2 gene promoter has been shown to harbor a
functional binding element for Ets-1, suggesting that it is a
target of the Ets transcription factor family [38].
Spry functions
In initial experiments to characterize the function of Spry1
and Spry2, HUVECs were employed to examine their role
in VEGF, FGF, and EGF signaling [23]. Forced expression
of Spry1 and Spry2 in endothelial cells inhibited VEGF-,
FGF-, and EGF-stimulated growth and sprouting. Interest-
ingly, these Spry isoforms only repressed FGF- and VEGF-
induced phosphorylation of MAPK and not that stimulated
by EGF, demonstrating that various RTK cascades were
differentially affected by Spry proteins. In another study,
Angiogenesis (2008) 11:53–62 55
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Spry4 function was examined in endothelial cells using a
combination of in vitro and in vivo experiments [39].
Endothelial cell proliferation, migration, and MAPK acti-
vation induced by either FGF2 or VEGF were inhibited by
Spry4 expression, and the Spry4-expressing cells arrested
in the G1/G2 phase of the cell cycle. Notably, Spry4 inhi-
bition could be overcome by a constitutively active form of
Ras, suggesting that Spry4 exerted its functions upstream
of Ras. Moreover, the cell cycle inhibitor p21 was induced
and phosphorylation of the cell cycle control protein Rb
was decreased, which correlated with the presence of Spry4
in these cells. Lastly, gene transfer-mediated expression of
Spry4 in the vascular endothelium of the mouse embryo
resulted in marked repression of sprouting and branch
formation of the yolk sac vasculature [39]. Thus, Spry
proteins are important regulators of RTK function (i.e.
growth and differentiation) in endothelial cells and inhibit
angiogenesis in in vitro and in vivo model systems.
Spry mechanisms of action
The exact mode of action for Spry proteins has been difficult
to ascertain, as noted by early reports examining the func-
tional role of the various Spry isoforms in different growth
factor pathways in diverse cell types and species [15–18, 40].
Vertebrate Spry proteins are now viewed as general modu-
lators of growth factor signaling, and for most RTK signaling
cascades, Spry proteins repress MAPK activation. For FGF
signaling, all mammalian Spry proteins inhibit FGF-induced
MAPK activation to varying degrees [41–43]. However, in
the case of EGF stimulation, Spry2 can potentiate MAPK
activation in some cell types [44–46]. This context-specific
dual function of Spry has also been illustrated for T-cell
receptor signaling where Spry1 acts either as an inhibitor or
as an enhancer depending on the differentiation state of the
T-cell [30]. In short, Spry modulation of RTK signaling is
very pliable and highly cell- and context-dependent.
All Spry isoforms possess a highly conserved N-terminal
tyrosine residue, which in the case of Spry1 and Spry2 is
phosphorylated upon EGF and FGF signaling and in the
case of Spry4 is phosphorylated upon FGF and insulin
signaling [24, 42, 47, 48]. Mutation of this tyrosine gener-
ates a dominant-negative Spry unable to inhibit FGF-
stimulated MAPK activation [24, 48, 49]. The Src family of
kinases is likely responsible for phosphorylation of Spry at
this conserved tyrosine, while Shp2 phosphatase is involved
in dephosphorylating this critical residue [48, 50–52].
FGF signaling
The FGF/FGFR signaling axis is important for endothelial
growth, migration, and morphogenesis and is critical for
angiogenesis in both normal and disease states [53]. To
elucidate the Spry mechanism of action, most studies have
focused on Spry2, the most highly conserved isoform
across vertebrates. Initially, both Spry1 and Spry2 have
been proposed to bind Grb2 via the N-terminal conserved
tyrosine residue, thus interrupting the signaling cascade
before MAPK can be activated [22, 43, 45, 49, 54]
(Fig. 1b). The role of Grb2 in Spry-mediated inhibition of
FGF-induced MAPK pathway has remained controversial.
Lao and co-workers discovered, using an FGFR overex-
pression system (i.e. long-term MAPK signaling), that
Spry2 requires an FGFR-induced conformational change
involving a cryptic PXXPXR motif on its C-terminus to
bind Grb2 via its N-terminal SH3 domain [42]. However, a
study involving acute FGF signaling (i.e. short-term
MAPK activation without FGFR overexpression) demon-
strated an uncoupling of Spry2–Grb2 binding from Spry-
mediated inhibition of MAPK activation [55]. This work
revealed that Spry2 harbors two Grb2-binding sites and that
a mutant hSpry2 lacking both sites still antagonized FGF
signaling. Thus, how FGF signaling is antagonized by Spry
may depend on the type and/or duration of the original
stimulus.
Post-translational modification of Spry likely plays a
central role in determining its function and activation sta-
tus. In unstimulated cells, Spry1 and Spry2 have been
found phosphorylated on serine residues [23]. Spry2 inhi-
bition of FGF signaling requires phosphorylation of
tyrosine 227 (Y227), which is dispensable for Spry2
potentiation of EGF signaling [56]. Recently, Lao and co-
workers reported that a change in Spry2 phosphorylation
status was required for the inhibition of FGFR-induced
MAPK activation [57]. Upon FGFR activation, Spry2 is
dephosphorylated by the protein phosphatase 2A (PP2A) at
highly conserved serine residues (S112 and S115) in the
Spry N-terminus, thus activating Spry [57]. PP2A com-
petes with the E3 ubiquitin ligase, c-Cbl, for binding to
Spry2, thus establishing two pools of Spry2-containing
complexes and striking a balance between Spry2 activation
and degradation. Hence, both tyrosine phosphorylation and
serine dephosphorylation are required for Spry2-mediated
inhibition of FGFR signaling (Fig. 1b).
Another characteristic of Spry proteins is their ability to
form homo- and hetero-complexes [24, 41, 48, 49]. In the
context of FGF signaling all four Spry isoforms have been
reported to interact with each other via their cysteine-rich
domains [43]. In a heterodimer of Spry1 and Spry4, Spry1
can bind to Grb2, while Spry4 interacts with Sos1. These
studies also revealed that the interaction between Spry1
and Spry4 was the most potent combination for inhibiting
FGF2-induced MAPK activation. Thus, the combinatorial
set of Spry isoforms within a cell determines the extent of
FGF signaling inhibition.
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EGF signaling
The role and components of the EGF-induced MAPK
cascade in normal endothelium are still under debate;
however, there is consensus that EGF signaling plays an
important role in tumor endothelium [58–60]. The function
of Spry in the EGF signaling cascade has been the most
controversial due to the different cell types that have been
examined. The general consensus is that Spry can poten-
tiate EGF-induced MAPK activation in certain cellular
contexts. The EGF receptor (EGFR) is normally rapidly
downregulated due to its interaction with the E3 ubiquitin
ligase, c-Cbl. However, Spry2 interferes with this interac-
tion and competes with the EGFR for c-Cbl-binding
preventing receptor internalization, thus sustaining EGFR-
mediated signaling [44, 46, 61, 62] (Fig. 1c). Moreover,
Spry2 binds CIN85, an endocytic adapter, thus regulating
the clustering of c-Cbl that is required for EGFR endocy-
tosis and degradation [63]. Other RTKs, such as the FGFR,
are also degraded by c-Cbl, and it is still not clear how Spry
discriminates between EGF and FGF signaling. In a recent
study, where Spry2 levels were reduced by RNA interfer-
ence, FGF signaling was increased, while EGF signaling
was reduced [56]. These experiments led to the discovery
that phosphorylation at a conserved tyrosine (Y227) dis-
criminates between the EGF and FGF signaling pathways,
suggesting that unidentified proteins bind to this C-terminal
region depending on the signaling context. More recently,
Kim et al. [64] described that Spry2 interfered with acti-
vated EGFR trafficking to late endosomes. Spry2 interacts
with hepatocyte growth factor-regulated tyrosine kinase
substrate (Hrs) in early endosomes. The Spry2–Hrs com-
plex disrupts the Hrs association with tumor susceptibility
gene 101, an interaction required for EGFR movement
from early to late endosomes, resulting in delayed EGFR
trafficking and perturbation of phospho-MAPK accumula-
tion in late endosomes. Thus, potentiation of EGF signaling
by Spry relies on interactions with proteins that are
involved in the endocytosis and degradation of EGFR.
VEGF signaling
VEGF-induced signal transduction is the most critical and
best studied signaling pathway in endothelial cells and
plays a central role in vascular development and in phys-
iological and pathological angiogenesis [65]. In endothelial
cells, VEGF binds to VEGF receptor (VEGFR) and acti-
vates MAPK via the phospholipase C gamma (PLC c) and
protein kinase C (PKC) pathway where PKC phosphory-
lates Raf1, thereby activating ERK/MAPK in a Ras-
independent manner [66] (Fig. 1a). Here, Spry-mediated
inhibition of VEGF signaling occurs via a different
mechanism as compared to FGF and EGF signaling [67]
(Fig. 1d). Spry4 binds to Raf1 via a highly conserved C-
terminal domain, thus ablating VEGF signaling by segre-
gating Raf1 away from the cascade. All Spry isoforms
carry this Raf1-binding domain (RBD) in their highly
conserved C-terminal domain suggesting that all Spry
isoforms may be capable of inhibiting VEGF signaling in a
similar manner.
Apparently, Spry mechanisms of action are as varied as
their target RTKs. For each signaling cascade studied in
depth so far, Spry proteins have evolved an inhibitory
strategy unique to each pathway.
Spry-interacting proteins and Spry activity
Spry proteins have accumulated a long list of interacting
and associated proteins that regulate Spry function, sta-
bility, and localization, many of which interact with the C-
terminal SPR domain (reviewed in [17, 18]). Included in
this list is Caveolin-1, a transmembrane protein and the
major architectural component of caveolae, flask-shaped
pits on the cell membrane [68]. Caveolin-1 promotes
capillary tube formation, and its role in regulating angio-
genesis has been underlined in transgenic overexpression
and knockout experiments in mice [69–72]. Caveolin-1
also inhibits RTK signaling, yet in a cell confluency-
dependent manner [73]. Caveolin-1 co-localizes and
immunoprecipitates with Spry1 and Spry2 [23]. Upon
further analysis, all Spry isoforms interact with Caveolin-1
and Spry binds to Caveolin-1 via its highly conserved
cysteine-rich C-terminal domain [41]. Caveolin-1 in turn
binds to the various Spry isoforms via two domains, a N-
terminal and a C-terminal domain. Spry proteins do not
require Caveolin-1 for their function nor for their mem-
brane targeting; however, Caveolin-1 acts cooperatively
with some Spry isoforms depending on whether the EGF or
FGF pathways are being stimulated. In summary, Caveo-
lin-1 modulates Spry activity in an isoform-, cell density-,
and growth factor-specific manner, suggesting that together
these two proteins fine tune growth factor signaling.
Recently, Necl-5, also known as poliovirus receptor/
CD155/Tage4, has been identified as a novel Spry2-inter-
acting protein [74]. Necl-5 is a mediator of contact
inhibition that forms a complex with integrin avb3, is
upregulated by PDGF and FGF, and is also found on
endothelial cells [74–76]. Necl-5 interacts with Spry2 in a
cell confluency-dependent manner and controls Spry2
tyrosine phosphorylation, thus modulating the PDGF-acti-
vated MAPK signaling pathway. This novel binding
partner demonstrates once again the importance of cell–cell
contacts in the fine-tuning of Spry-mediated inhibition of
RTKs.
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Another previously described Spry-interaction partner,
TESK1, a cofilin kinase, has now been shown to interact
with all Spry proteins [77]. Initially, TESK1 was described
as a Spry4-binding protein that co-localizes with Spry4 in
endosomes [20]. Spry4 binds TESK1 via its C-terminal
cysteine-rich domain and inhibits TESK1 activity resulting
in decreased cell spreading [78]. TESK1 itself inhibits
Spry2 activity by interfering with its subcellular localiza-
tion so as to prevent serine dephosphorylation and also
binding to Grb2 [77].
Regulation of Spry protein stability and activity
Spry protein stability and turnover are important determi-
nants of how this family of negative feedback inhibitors
affects endothelial cell homeostasis. While growth factor
stimulation does induce Spry gene transcription [23, 24,
79], it also results in proteolytic degradation of Spry pro-
teins [45, 46, 80]. This negative feedback loop system is
thought to regulate Spry function temporally as a conse-
quence of RTK stimulation [17, 18, 81]. Three recent
studies have demonstrated that Spry stability is regulated in
a complex manner [82–84]. As mentioned above, Spry
proteins are phosphorylated on serine residues in unstim-
ulated cells and are further phosphorylated on serine
residues upon EGF and FGF stimulation [23, 82]. Phos-
phorylation of Spry2 at S112 and S121 is mediated by the
MAPK-interacting kinase 1, Mnk1, which interferes with
Spry2 tyrosine phosphorylation and thus stabilizes Spry2.
Degradation of Spry2 is linked to phosphorylation of the
conserved N-terminal tyrosine residue. A mutant version of
Spry2 lacking all serine and tyrosine phosphorylation sites
prevents Spry2 degradation, and a mutant version of Spry2
lacking the serine phosphorylation sites is no longer able to
inhibit FGF-induced MAPK activation [82]. Together these
data reveal that Spry stability and function require both
tyrosine and serine phosphorylation.
Using a yeast two-hybrid screen, Nadeau and co-work-
ers recently reported that Spry proteins interact with and
are targets of the E3 ubiquitin ligase, ‘‘seven-in-absentia
homolog 2’’ (SIAH2) [84]. Notably, SIAH2-mediated
proteasomal degradation of Spry is independent of its
tyrosine phosphorylation of the N-terminal tyrosine. These
results uncover another mechanism for regulating Spry
protein levels and function.
Finally, transforming growth factor-beta 1 (TGF-b1) has
been shown to regulate Spry2 at both the mRNA and
protein levels [83]. TGF-b1 plays a critical role in vessel
maturation and in the initial stages of angiogenesis [85].
TGF-b1-mediated degradation of endogenous Spry2 pro-
tein is independent of MAPK activation, cannot be rescued
by addition of EGF, and occurs in the lysosome. Further-
more, TGF-b1 induces a transcriptional downregulation of
Spry2 that is due to diminished mRNA production and
requires de novo protein synthesis and histone deactylase
activity. Lastly, Spry2’s modulation of FGF and EGF
signaling declined in cells pretreated with TGF-b1, sug-
gesting that TGF-b signaling, possibly via the Smad
proteins, can regulate Spry2 function by altering its mRNA
and protein levels. In summary, Spry protein and mRNA
turnover can be regulated by various signals, some of
which are RTK-dependent while others are not (summa-
rized in Fig. 2].
Spry and nitric oxide
Recently, it has been reported that Spry2 can assemble into
large, spherical 24-mers with an iron–sulfur complex sug-
gesting that they can function as redox sensors as these
structures exist in oxidized, reduced, or nitrosylated forms
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Fig. 2 Regulation of Spry2
stability. A diagram depicting
the RTK-dependent and RTK-
independent pathways that
control Spry2 protein turnover.
There are at least five signaling
pathways that regulate Spry2
accumulation in the cell:
transcriptional upregulation by
the MAPK signaling pathway,
serine phosphorylation by
Mnk1, tyrosine phosphorylation
by Src, ubiquitinylation by
SIAH2, and TGF-b1-mediated
transcriptional downregulation
and lysosomal degradation [23,
24, 79, 82–84]. pY55 denotes
the N-terminal tyrosine
phosphorylation on Spry2
58 Angiogenesis (2008) 11:53–62
123
[86]. Notably, based on these observations it was proposed
that these Spry2 complexes can hold an electrical charge
and exhibit properties akin to an intracellular battery.
Curiously, ectopic expression of nitric oxide synthase
(NOS) in Drosophila mimics the dSpry mutation of
increased tracheal branching [87]. In mammals, endothelial
NOS (eNOS) is essential for endothelial cell proliferation
and is required for vessel morphogenesis, branching, and
stabilization (reviewed in [88]). Furthermore, the Spry-
interacting protein, Caveolin-1, binds to and inhibits eNOS
activity [89]. Thus, it is tempting to speculate that, in
endothelial cells, Spry2 has additional functions that
involve changes to its redox state and eNOS. To what
extent, if any, these modifications affect Sprys’ MAPK
inhibitory activities has yet to be determined.
Murine Spry knockout studies
The generation of Spry null mice has yielded exciting new
information about Spry function as well as confirming the
central role of Sprys in modulating branching morpho-
genesis and growth factor signaling. Mice lacking Spry1
exhibit kidney and ureteric bud defects arising from
improper branching morphogenesis [27, 90]. These mal-
formations arise due to de-regulated signaling of GDNF by
its cognate receptor c-Ret, which is essential for proper
kidney development. Spry2 null mice have been generated
independently in two laboratories. In one report, Spry2 null
mice are viable, have a shortened life span, and exhibit
hearing loss due to aberrant FGF8 signaling that results in
malformation of the organ of Corti [91]. The other Spry2
knockout mouse line also exhibits a reduced lifespan and,
in addition, a severe gastrointestinal phenotype character-
ized by enteric nerve dysplasia presumably due to GDNF
hyperactivity [92].
More recently, two independent Spry4 null mouse lines
have been reported [93, 94]. In a first report, these mice were
used to show that Spry2 and Spry4 control tooth develop-
ment by antagonizing FGF signaling from different tissues;
while Spry2 was expressed in the epithelium, Spry4 was
found in the mesenchyme [93]. In a second report, Spry4 null
mice showed reduced viability due to mandible defects,
while the surviving mice exhibited growth retardation and
polysyndactyly (i.e. fusion and duplication of forelimb dig-
its) [94]. Also, Spry2/Spry4 double knockout mice were
embryonic lethal with the majority of these embryos dying at
E12.5 with apparent morphogenetic abnormalities of the
head, lung and limbs, including cyclopia. Together, these
data suggest that Spry2 and Spry4 have redundant activities
during embryonic development. Although Spry overex-
pression markedly affects endothelial cell proliferation, tube
formation, and angiogenesis in experimental models (see
above), none of the Spry knockouts described thus far
exhibits an overt vascular phenotype.
Sprouty-related proteins, Spreds
Spreds are related structurally and functionally to Spry
proteins and have recently been reviewed [19]. Like Spry
proteins, Spreds inhibit the MAPK pathway induced by
various mitogens and share with Sprys the highly con-
served cysteine-rich C-terminal SPR domain. Studies in
Xenopus have highlighted the functional differences
between Spry and Spred proteins. While in Xenopus Spry
proteins inhibit PKC d and calcium signaling, Spred pro-
teins interfere with Ras–MAPK signaling [95]. In
mammals, there seems to be more overlap in the signaling
pathways that can be targeted by both Spry and Spreds, but
Spred function tends to be more focused on MAPK inac-
tivation [19]. A recent study examining the overlapping
roles of Spred1 and Spred2 in double knockout mice
demonstrates that Spreds are essential for development of
the lymphatic system [96]. These mice are embryonic
lethal at E12.5–E15.5 and display hemorrhages, edemas,
and dilated lymphatic vessels, suggesting incomplete par-
titioning of lymphatic vessels from blood vessels.
Expression of Spred1 and Spred2 is restricted to lymphatic
endothelial cells, while Spry2 and Spry4 are found in both
blood and lymphatic endothelial cells, suggesting that Spry
function cannot replace Spred function in lymphatic
endothelial cells. Apparently, Spred1 and Spred2 are able
to repress the VEGF-C/VEGFR3-mediated signaling
pathway. In contrast, Spry4 exerts only a very moderate
inhibitory effect on this pathway. Curiously, both Spred
proteins and Spry4 repress VEGF-A-induced MAPK acti-
vation via VEGFR2 [96]. In summary, while the Spred and
Spry families share common features and activities, they
have evolved to exert distinct and specific roles in modu-
lating RTK signaling cascades.
Summary and conclusions
The critical contribution of Spry proteins in the control of
signal transduction pathways in a variety of cell types,
including endothelial cells, is well established. Nearly a
decade has passed since they were first identified as
antagonists of the FGF-induced signaling pathway. Ever
since, their role in biology has expanded to encompass
many more signaling pathways and biological processes,
mostly involving an inhibitory function in RTK-induced
MAPK signaling. While there are many open questions
regarding Sprys’ mechanisms of action in individual sig-
naling pathways, it is now clear that Spry proteins are
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multi-functional and themselves highly regulated in their
expression and function. Continuing studies will shed more
light on the complexity of Spry function in controlling the
multiple outputs of mitogen-induced cascades in physio-
logical and pathological processes in general and in
angiogenesis in particular. Novel insights about their
molecular function may set the stage for the development
of innovative therapeutic approaches to interfere with
RTK-mediated pathological processes.
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